MGMT and glioblastoma: Unfortunately, despite promising data from phase II studies [85–87], cilengitide did not improve patient survival in a multicenter, randomized, open-label phase III trial in newly diagnosed O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylated glioblastoma when added to temozolomide-based CRT (CENTRIC EORTC 26071-22072 study, NCT00689221) [88].